<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45223">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517580</url>
  </required_header>
  <id_info>
    <org_study_id>MK7-002</org_study_id>
    <nct_id>NCT02517580</nct_id>
  </id_info>
  <brief_title>Vitamin K2 Supplementation and Arterial Stiffness in the Renal Transplant Population (The KING Trial)</brief_title>
  <acronym>KING</acronym>
  <official_title>Vitamin K2 Supplementation and Effect on Arterial Stiffness Progression in the Renal Transplant Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lebanese American University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Omicron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lebanese American University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single arm, single center clinical trial that aims to evaluate the effect of
      8 weeks of vitamin K2 replacement (360 mcg/day) on the progression of arterial stiffness in
      stable renal transplant patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction from baseline in carotid-femoral pulse wave velocity at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central pressure by ambulatory hemodynamic measurement (Mobil-O-Graph) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in augmentation index by ambulatory hemodynamic measurement (Mobil-O-Graph) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood concentration of dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Arterial Stiffness</condition>
  <condition>Vitamin K2 Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin K2 (MK7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin K2 (MK7) 360 mcg/day PO once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin K2 (MK7)</intervention_name>
    <arm_group_label>Vitamin K2 (MK7)</arm_group_label>
    <other_name>MenaQ7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Functional renal graft

          -  Stable renal function for at least 3 months prior to enrollment

        Exclusion Criteria:

          -  History of thrombotic events

          -  Diagnosed coagulopathy

          -  Cardiovascular event in the past month prior to enrollment

          -  Current or planned pregnancy

          -  Lactation

          -  Soy allergy

          -  Concomitant or recent (past 6 months) use of supplements that contain vitamin K

          -  Warfarin treatment

          -  Known intestinal malabsorption or hypomotility syndromes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sola Aoun Bahous, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lebanese American University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lebanese American University Medical Center - Rizk Hospital</name>
      <address>
        <city>Ashrafieh</city>
        <state>Beirut</state>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 6, 2016</lastchanged_date>
  <firstreceived_date>August 5, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lebanese American University</investigator_affiliation>
    <investigator_full_name>Sola Aoun Bahous, M.D. Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Division of Nephrology and Transplantation</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
